Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | MicrobiomeTrials← Back to trialsNCT06995677
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-06-27Est. Completion: 2028-02
Enrollment target: 90 participants Locations- Urology Centers of Alabama, Homewood, Alabama, United States
- Arkansas Urology, Little Rock, Arkansas, United States
- Tri Valley Urology - Murrieta, Murrieta, California, United States
- Eisenhower Medical Associates, Rancho Mirage, California, United States
- Om Research LLC, San Diego, California, United States
- Associated Urological Specialists, Chicago Ridge, Illinois, United States
- Duly Health and Care, Lisle, Illinois, United States
- Urology of Indiana, Greenwood, Indiana, United States
- First Urology, Jeffersonville, Indiana, United States
- University of Kansas Medical Center (KUMC), Kansas City, Kansas, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Greater Boston Urology, Plymouth, Massachusetts, United States
- Specialty Clinical Research of St. Louis, St Louis, Missouri, United States
- Atlantic Health System, Morristown, New Jersey, United States
- New Jersey Urology, LLC (Summit Health - Washington Township), Voorhees Township, New Jersey, United States
- Icahn School of Medicine at Mount Sinai (ISMMS) - Mount Sinai Queens - Infusion Center, Astoria, New York, United States
Other microbiome trials you might be interested in
Urinary Bladder Neoplasms
Background:
Non-muscle-invasive bladder cancer is in the early stages. But it usually comes back after treatment. The d…
Bethesda, United StatesCompleted Aug 1, 2022
Bladder (Urothelial, Transitional Cell) CancerAntibody-drug ConjugatesImmunotherapyChemotherapySystemic Therapy
This randomized controlled trial aims to evaluate the efficacy and safety of antibody-drug conjugate (ADC) plus immunoth…
NYU Langone Health, New York, New York, United StatesMemorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers, New York, New York, United StatesAssociated Medical Professionals of NY, Syracuse, New York, United StatesState University of New York (SUNY) Upstate Medical University, Syracuse, New York, United StatesThe Bronx Veterans Medical Research Foundation, Inc., The Bronx, New York, United StatesDuke Cancer Institute, Durham, North Carolina, United StatesAssociate Urologist of North Carolina, Raleigh, North Carolina, United StatesThe James at Brain and Spine Hospital (OSU), Columbus, Ohio, United StatesOregon Urology Institute, Springfield, Oregon, United StatesMidLantic Urology, Bala-Cynwyd, Pennsylvania, United StatesKeystone Urology Specialists, Lancaster, Pennsylvania, United StatesMedical University of South Carolina, Charleston, South Carolina, United StatesCarolina Urologic Research Center, Myrtle Beach, South Carolina, United StatesLowcounty Urology Clinics, P.A., North Charleston, South Carolina, United StatesConrad Pearson-Memphis, Germantown, Tennessee, United StatesUrology Associates PC, Nashville, Tennessee, United StatesUrology Austin, Austin, Texas, United StatesUrology Clinics of North Texas, Dallas, Texas, United StatesBaylor College of Medicine, Houston, Texas, United StatesUrology San Antonio, San Antonio, Texas, United StatesEpworth Freemasons-Victoria Parade, Richmond, Victoria, AustraliaIstituti Fisioterapici Ospitalieri (IFO), Rome, Italy, ItalyIstituto Europeo di Oncologia, Milan, ItalyAzienda Ospedaliero Universitaria Pisana - Ospedale Santa Chiara, Pisa, ItalyASL Napoli 2 Nord - Ospedale Santa Maria delle Grazie, Pozzuoli, ItalyHospital del Mar, Barcelona, Spain, SpainHospital Clínico San Carlos, Madrid, Spain, SpainHospital Universitario 12 de Oc, Madrid, Spain, SpainHospital Quirón Barcelona, Barcelona, SpainMD Anderson Cancer Center - Madrid, Madrid, SpainHospital Universitario Ramón y Cajal, Madrid, SpainHospital Universitario Marqués de Valdecilla, Santander, SpainTianjin, China
Est. completion Mar 1, 2028